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Abstract
Tetherin, also known as BST2, CD317 or HM1.24, was recently identified as an interferon-inducible host–cell factor that
interferes with the detachment of virus particles from infected cells. HIV-1 overcomes this restriction by expressing an
accessory protein, Vpu, which counteracts tetherin. Since lentiviruses of the SIVsmm/mac/HIV-2 lineage do not have a vpu
gene, this activity has likely been assumed by other viral gene products. We found that deletion of the SIVmac239 nef gene
significantly impaired virus release in cells expressing rhesus macaque tetherin. Virus release could be restored by
expressing Nef in trans. However, Nef was unable to facilitate virus release in the presence of human tetherin. Conversely,
Vpu enhanced virus release in the presence of human tetherin, but not in the presence of rhesus tetherin. In accordance
with the species-specificity of Nef in mediating virus release, SIV Nef downregulated cell-surface expression of rhesus
tetherin, but did not downregulate human tetherin. The specificity of SIV Nef for rhesus tetherin mapped to four amino
acids in the cytoplasmic domain of the molecule that are missing from human tetherin, whereas the specificity of Vpu for
human tetherin mapped to amino acid differences in the transmembrane domain. Nef alleles of SIVsmm, HIV-2 and HIV-1
were also able to rescue virus release in the presence of both rhesus macaque and sooty mangabey tetherin, but were
generally ineffective against human tetherin. Thus, the ability of Nef to antagonize tetherin from these Old World primates
appears to be conserved among the primate lentiviruses. These results identify Nef as the viral gene product of SIV that
opposes restriction by tetherin in rhesus macaques and sooty mangabeys, and reveal species-specificity in the activities of
both Nef and Vpu in overcoming tetherin in their respective hosts.
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Introduction
Efforts to elucidate the function of the HIV-1 Vpu protein
recently led to the identification of an interferon-inducible, host-
cell factor that interferes with the detachment of virions from
infected cells [1,2]. Vpu-deleted strains of HIV-1 exhibit a cell-type
dependent defect in the release of virus particles from cells
[3,4,5,6,7,8]. In certain human cell lines, such as HeLa, Hep-2
and Jurkat cells, virus particles assemble and bud from the plasma
membrane, but fail to detach from the cell surface [6,9,10]. These
particles then become internalized where they accumulate in
endosomal compartments [6,9]. In other cell types, such as 293T,
HOS and Cos-7 cells, Vpu is not required for virion release [9,10].
Varthakavi and Spearman demonstrated that heterokaryon
fusions of permissive and non-permissive cells exhibited a non-
permissive phenotype for the release of vpu-deleted HIV-1 [10].
These experiments pointed to the presence of an inhibitor of virus
release in Dvpu-restrictive cells [10]. Subsequent studies revealed
that the putative restriction factor was an interferon-inducible
protein exposed on the cell surface [9,11]. These observations
quickly led Neil and Bieniasz to identify bone marrow stromal
antigen 2 (BST2), also known as CD317 or HM1.24, from an
expression analysis of IFNa-treated cells as the cellular gene
product responsible for the restriction of vpu-deficient HIV-1 [1].
Based on a proteomic analysis of viral modulators of cell
membrane proteins that was actually the first study to suggest a
role for Vpu in the downmodulation of BST2 [12], Van Damme
and Guatelli independently identified BST2 as the restriction
factor for HIV-1 Dvpu, and further demonstrated that Vpu-
mediated downregulation of BST2 facilitated virion release [2].
For its role in inhibiting the detachment of virus particles from the
surface of infected cells, BST2 was re-named ‘‘tetherin’’ [1].
Tetherin is an integral membrane protein with a number of
peculiar features that suggests it plays a direct role in inhibiting the
release of virions from infected cells. The N-terminus of the
molecule is located in the cytoplasm, followed by a transmem-
brane domain and an extracellular coiled-coil domain [13,14].
The C-terminus of the protein contains a predicted cleavage site
for the addition of a glycosyl-phosphatidylinositol (GPI) anchor
[13,14]. Hence, tetherin is predicted to adopt an unusual topology
in which both ends of the protein are anchored in the cell
membrane [13,14]. Tetherin also associates with cholesterol-rich
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assembly and release for HIV-1 as well as for other enveloped
viruses [15,16,17,18,19]. Thus, it has been proposed that tetherin
may become incorporated into enveloped viruses as they attempt
to bud from the cell surface and may prevent their release by
bridging them to the plasma membrane [1,2,20]. Interactions
between the cytoplasmic domain of tetherin and the cellular
endocytosis machinery may then mediate the internalization of
captured virions for degradation within endosomal compartments
[1,2,9,11,20].
Among the primate lentiviruses, only the HIV-1/SIVcpz and
SIVgsn/mon/mus lineages are known to have a vpu gene
[21,22,23,24]. Given evidence that tetherin has broad antiviral
activity against a diverse range of enveloped viruses, including
retroviruses, filoviruses and arenaviruses [1,25,26,27], it is likely
that other lentiviruses have also evolved countermeasures to
overcome restriction by tetherin. In the case of HIV-2, the
envelope glycoproteins of certain isolates have Vpu-like activity
that can enhance the release of virions from restrictive cells
[28,29,30,31]. Phylogenetic and epidemiological evidence suggest
that HIV-2 and SIVmac both originated as a result of the cross-
species transmission of SIVsmm from sooty mangabeys to humans
and from sooty mangabeys to rhesus macaques respectively
[32,33,34,35,36]. The common origin of these viruses has
therefore led to speculation that SIV may also use its envelope
glycoprotein to overcome restriction by tetherin.
As a consequence of the ongoing evolutionary conflict between
viral pathogens and host cell defenses, many antiviral restriction
factors have acquired amino acid differences that are important
host-range determinants of viral infection [37,38]. TRIM5a was
first identified as the post-entry block to HIV-1 infection of cells
from rhesus macaques [39], and differences in the B30.2 (SPRY)
domain of TRIM5a are now recognized as important host-range
determinants of the primate lentiviruses [40,41,42,43]. Likewise,
species-specific differences in the APOBEC family of cytidine
deaminases are significant host-range determinants for diverse
retroviruses [44,45,46,47]. A single amino acid difference in
simian versus human APOBEC3G accounts for the inability of
HIV-1 Vif to overcome this restriction in Old World monkeys
[48,49,50]. Comparison of the amino acid sequences of tetherin
orthologues from different mammalian species suggests that
tetherin may also be rapidly evolving under positive selection in
response to viral pathogens [13,51]. Indeed, recent studies have
now demonstrated that the ability of Vpu to antagonize tetherin is
species-specific [51,52].
Here we show that SIV Nef overcomes restriction by rhesus
macaque and sooty mangabey tetherin, but not human tetherin.
Conversely, HIV-1 Vpu counteracts restriction by human
tetherin, but is ineffective against macaque or mangabey tetherin.
The specificity of SIV Nef for rhesus tetherin mapped to a four
amino acid sequence in the cytoplasmic domain that is missing
from the human protein, whereas the specificity of HIV-1 Vpu for
human tetherin mapped to amino acid differences in the trans-
membrane domain. Thus, similar to TRIM5a and APOBEC3G,
species-specific differences in tetherin may influence the host-
range of primate lentiviruses.
Results
SIV Nef counteracts restriction by rhesus tetherin
Deletion mutants of SIV were tested for particle release in cells
expressing tetherin to identify the viral gene product(s) that oppose
this restriction factor. Wild-type and vpu-deleted strains of HIV-1
were also tested as controls. These assays were performed by
transfection of 293T cells with full-length HIV-1 NL4-3 and
SIVmac239 proviral DNA mutants together with expression
constructs for either human or rhesus tetherin (hBST2 or rBST2).
293T cells were selected for these assays since previous studies
have shown that these cells do not express endogenous tetherin in
the absence of IFNa induction [1,11]. Virus release was measured
by HIV-1 p24 and SIV p27 antigen-capture ELISA at 0, 2, 20 and
200 ng of plasmid DNA for each tetherin expression construct
(Fig. 1). Virion release for each strain was then compared as a
percentage of maximal particle release in the absence of tetherin.
Consistent with previous reports, HIV-1 Dvpu was more
sensitive to restriction by human tetherin than wild-type HIV-1
(Fig. 1A) [1,2]. In the case of SIV, particle release for wild-type
virus, and for each of the deletion mutants, was inhibited to a
similar or greater extent than for HIV-1 Dvpu (Fig. 1A). Thus, SIV
appeared to be unable to counteract restriction by human tetherin.
We therefore compared virion production in the presence of
rhesus tetherin. Wild-type SIV was considerably more resistant
than HIV-1 to restriction by rhesus tetherin (Fig. 1B). Moreover,
both wild-type and vpu-deleted HIV-1 exhibited similar suscepti-
bility to rhesus tetherin (Fig. 1B). Thus, HIV-1 also appeared to be
unable to counteract restriction by rhesus tetherin. The inherent
susceptibility of HIV-1 to rhesus tetherin and SIV to human
tetherin suggested that the countermeasures used by these viruses
were species-specific.
In cells expressing rhesus tetherin, the greatest reduction in
particle release was observed for SIV Dnef. Compared to wild-type
SIV, SIV Dnef was inhibited 2- to 22-fold in the presence of rBST2
(Fig. 1B). A lesser 1.5- to 5-fold reduction was also observed for
SIV Denv. However, similar reductions in virus release were also
observed for SIV Denv in the presence of hBST2 (Fig. 1A), and in
the absence of tetherin (Fig. 1C & D). Thus, it is unclear to what
extent these differences may reflect additional non-specific effects
of envelope on virus assembly and release. SIV mutants with
deletions in vpr and vpx were also tested, but elimination of these
genes did not significantly impair virus release in the presence of
either human or rhesus tetherin (data not shown). These
experiments therefore pointed to a role for the SIV Nef protein
in overcoming restriction by rhesus tetherin.
Author Summary
Tetherin was recently identified as a host–cell factor that
interferes with the detachment of virus particles from
infected cells. HIV-1 overcomes the antiviral effects of
tetherin by expressing Vpu, which mediates the degrada-
tion of tetherin. While tetherin has broad activity against
diverse types of viruses, only a few of the primate AIDS
viruses express Vpu. Simian immunodeficiency virus (SIV)
does not have a vpu gene. Since SIV infection of the rhesus
macaque is an important animal model for AIDS vaccine
development, we set out to determine how SIV overcomes
restriction by tetherin in this species. We found that the
SIV Nef protein could counteract rhesus macaque tetherin,
but not human tetherin. Conversely, the HIV-1 Vpu protein
counteracted human tetherin, but not rhesus tetherin. The
specificity of Nef for rhesus tetherin mapped to four amino
acids in the cytoplasmic domain of the molecule that are
missing from human tetherin, whereas the specificity of
Vpu for human tetherin mapped to amino acid differences
in the transmembrane domain. These observations identify
a role for the SIV Nef protein in counteracting tetherin, and
reveal species-specificity in the activities of both Nef and
Vpu in overcoming tetherin in their respective hosts.
Species-Specificity in Overcoming Tetherin
PLoS Pathogens | www.plospathogens.org 2 May 2009 | Volume 5 | Issue 5 | e1000429To confirm that these results were due to the effects of tetherin
on particle release rather than on viral protein expression, we
compared levels of the SIV p55 Gag protein in cells to the
accumulation of p27 capsid in cell culture supernatant by western
blot analysis. For wild-type SIV, SIV Denv and SIV Dnef, similar
amounts of the p55 Gag protein were detected in cell lysates over a
0 to 50 ng range of plasmid DNA for both hBST2 and rBST2
(Fig. 2). In cells expressing human tetherin, there was a dose-
dependent decrease in the accumulation of p27 recovered from
the cell culture supernatant for each of these viruses (Fig. 2A & B).
A similar reduction in p27 was also observed for SIV Dnef at
increasing levels of rhesus tetherin (Fig. 2B). These reductions in
supernatant were accompanied by increases in cell-associated p27.
However, p27 levels in supernatant for wild-type SIV and SIV
Denv were less sensitive to the effects of rhesus tetherin, as reflected
by more consistent p27/p55 (supernatant/cell lysate) ratios
(Fig. 2B). Although a partial reduction in p27 was observed for
wild-type SIV and SIV Denv under conditions of overexpression,
suggesting that the ability to overcome restriction was saturable,
the p27 band remained detectable even at 50 ng of the rBST2
expression construct (Fig. 2B). Thus, these results support a role for
the SIV Nef protein in opposing the inhibition of vrus release by
tetherin.
Species-specificity of SIV Nef and HIV-1 Vpu in
counteracting restriction by tetherin
The capacity of SIV Nef and HIV-1 Vpu to restore particle
release in trans in the presence of human and rhesus tetherin was
tested to further investigate the species-specificity of these viral
proteins. Virus release for SIV Dnef and HIV-1 HXB2, a vpu-
deficient strain of HIV-1, was measured by antigen-capture
ELISA, and by infectivity on GHOST cells expressing CXCR4
and CCR5 (GHOST X4/R5 cells) [53]. The results of these assays
are presented as total p24/p27 release (Fig. 3A & E), or as the
frequency of infected cells following inoculation of GHOST X4/
R5 cells with cell culture supernatant (Fig. 3C & G). The data are
also presented as the percentage of maximal release in the absence
of tetherin to control for additional effects of Nef and Vpu on
Figure 1. Identification of Nef as the viral gene product of SIV that counteracts restriction by tetherin. SIV, SIV Denv, SIV Dnef, HIV-1 and
HIV-1 Dvpu were tested for particle release in the presence of human (hBST2) and rhesus (rBST2) tetherin. Virus production as a percentage of
maximal particle release in the absence of tetherin is shown at increasing amounts of plasmid DNA for hBST2 (A) and rBST2 (B). The mean and
standard deviation (error bars) for total p27 release is also shown for wild-type SIV, SIV Denv and SIV Dnef at the indicated amounts of DNA for hBST2
(C) and rBST2 (D). 293T cells were transfected in duplicate with proviral DNA constructs based on SIVmac239 and HIV-1 NL4-3 together with expression
constructs for either hBST2 or rBST2 (0, 2, 20 and 200 ng). Differences in the amount of plasmid DNA in each transfection were compensated by the
addition of empty vector (pcDNA3). After 48 hours, the amount of virus released into the cell culture supernatant was measured by HIV-1 p24 and SIV
p27 antigen-capture ELISA.
doi:10.1371/journal.ppat.1000429.g001
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(Fig. 3B, D, F & H). In each case, Vpu restored particle release in
cells expressing human tetherin, and SIV Nef restored particle
release in cells expressing rhesus tetherin, but not vice versa
(Fig. 3A–H). Hence, these results confirmed the species-specific
activity of both HIV-1 Vpu and SIV Nef in opposing restriction by
tetherin.
In cells expressing rhesus tetherin, SIV Nef enhanced p27 release
for SIV Dnef 8.1-fold and p24 release for HIV-1 HXB2 12.5-fold
(Fig. 3B & F). Similar corresponding increases were also observed in
the amount of infectious virus (Fig. 3D & H). To verify that the
activity of SIV Nef in counteracting rhesus tetherin was not the
result of protein overexpression, Nef mutants with amino acid
substitutions at positions predicted to broadly disrupt functional
activities of Nef, without altering protein folding or stability, were
also tested [54]. A glycine to alanine substitution in the N-terminal
myristoylation site (G2A), which disrupts the localization of the
protein to cellular membranes, significantly reduced the ability of
Nef to facilitate virus release in the presence of rhesus tetherin
(Fig. 3). Likewise, amino acid substitutions in a putative cholesterol
recognition motif (crm
2;L 129R, Y133A and Y134A), previously
reported to disrupt the association of HIV-1 Nef with cholesterol-
rich lipid microdomains [54], completely abolished this activity of
the SIV Nef protein (Fig. 3). Western blot analysis confirmed that
the G2A and crm
2 mutants were expressed at similar levels to the
wild-type SIV Nef protein, although a minor band representing a
potential degradation product of the crm
2 mutant was observed
(Fig. 3I). These results indicate that the activity of Nef in
counteracting rhesus tetherin does not simply reflect a non-specific
effect of protein overexpression. These results further suggest that
theabilityofSIVNeftoovercomerestrictionbyrhesustetherin may
depend on its localization to cellular membranes.
Figure 2. Dose-dependent reduction in the accumulation of SIV p27 in the cell culture supernatant relative to p55 Gag in cells at
increasing expression levels of tetherin. The accumulation of SIV p27 capsid in the cell culture supernatant relative to p55 Gag in cell lysates
was compared for wild-type SIV, SIV Denv and SIV Dnef at increasing expression levels of human and rhesus tetherin. 293T cells were transfected with
proviral DNA for wild-type SIV, SIV Denv or SIV Dnef together with 0, 2, 10 and 50 ng of plasmid DNA for hBST2 (A) or rBST2 (B). Forty-eight hours
post-transfection, virus was recovered from the culture supernatant by centrifugation and cell lysates were prepared. Proteins were separated on a
10% SDS-polyacrylamide gel, transferred to a PVDF membrane and probed with monoclonal antibodies to p27/p55 Gag (183-H12-5C) and to BST2
(HM1.24). The blots were then probed with an HRP-conjugated goat anti-mouse secondary antibody, developed in chemiluminescent substrate and
visualized using a Fujifilm Image Reader LAS 3000. Band intensities for p27 in virions and p55 in cell lysates were determined using the Image J
Software (Rasband, W.S., Image, U.S. NIH, Bethesda, MD, http://rsb.info.nih.gov/ij, 1997–2008) and compared as p27/p55 ratios. ‘ND’ indicates that the
p27 band was below the limit of detection.
doi:10.1371/journal.ppat.1000429.g002
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PLoS Pathogens | www.plospathogens.org 5 May 2009 | Volume 5 | Issue 5 | e1000429We also observed a partial effect of HIV-1 Nef on virus release.
HIV-1 Nef resulted in a 3.8-fold increase in SIV p27 release and a
1.9-fold increase in HIV-1 p24 release in cells expressing rhesus
tetherin (Fig. 3B & F). Consistent with the previously documented
role for Nef in infectivity enhancement [55,56,57,58,59], this effect
was greater (3.5-fold) when HIV-1 release was measured by
infectivity on GHOST X4/R5 cells rather than by p24 ELISA
(Fig. 3F & H). However, HIV-1 Nef did not significantly increase
the release of either SIV Dnef or HIV-1 HXB2 in cells expressing
human tetherin. Although HIV-1 Nef activity against rhesus
tetherin may seem at odds with the adaptation of HIV-1 for
replication in humans, it is conceivable that conserved sequences
in Nef, possibly maintained by virtue of their role in other
functional activities of the protein, contribute to a basal level of
HIV-1 Nef activity against rhesus tetherin.
In addition to facilitating particle release, Vpu also enhanced
HIV-1 infectivity. While Vpu increased p24 release by 3.7-fold,
infectivity was increased by 27.1-fold in the presence of human
tetherin (Fig. 3F & H). This represents a 5-fold increase in HIV-1
particle infectivity. In contrast to the infectivity enhancement
afforded by Nef, this effect was not observed in the absence of
tetherin or in cells expressing rhesus tetherin (Fig. 3G). Further-
more, Vpu did not increase the infectivity of SIV Dnef (Fig. 3B &
D). Thus, the infectivity enhancement afforded by Vpu appears to
be directly related to its role in counteracting human tetherin and
to be specific for HIV-1. These results are consistent with previous
observations [1,2,52], and suggest that Vpu may have an under
appreciated role in enhancing the infectivity of HIV-1 that
contributes to its activity in overcoming restriction by tetherin.
The SIV envelope glycoprotein does not rescue virion
release in the presence of human or rhesus tetherin
Since deletion of the env gene resulted in a modest increase in
the sensitivity of SIV to both human and rhesus tetherin, and the
envelope glycoproteins of certain HIV-2 isolates have been shown
to have Vpu-like activity [28,29,30,31], we further examined the
ability of the SIV envelope glycoprotein to oppose restriction by
tetherin. The relative contribution of SIV Env versus SIV Nef to
particle release was compared for an env- and nef-deleted strain of
SIV (SIV DenvDnef) in cells expressing human and rhesus tetherin.
We also tested the envelope glycoproteins of two closely related
HIV-2 isolates; one with Vpu-like activity, HIV-2 ROD10 Env,
and one without, HIV-2 ROD14 Env [30,31]. Consistent with
previous reports [30,31], HIV-2 ROD10 Env enhanced virus
release in cells expressing both human and rhesus tetherin,
whereas HIV-2 ROD14 Env did not (Fig. 4). These results suggest,
perhaps not surprisingly, that the HIV-2 ROD10 envelope
glycoprotein has a role in counteracting viral inhibition by
tetherin, but unlike Vpu or Nef, this activity is not species-specific.
However, similar to HIV-2 ROD14 Env, SIV Env failed to rescue
virus release in cells expressing either human or rhesus tetherin
(Fig. 4). In contrast, SIV Nef increased p27 release by more than
12-fold in cells expressing rhesus tetherin (Fig. 4). The inability to
detect a significant increase in virus release under conditions of
SIV Env overexpression further suggests that the SIV envelope
glycoprotein does not play a major role in counteracting restriction
by tetherin.
SIV Nef downregulates rhesus tetherin from the cell
surface
Since Nef is known to downregulate a number of proteins from
the cell surface [60], and Vpu has been shown to downregulate
tetherin [2], we asked whether SIV Nef could also downregulate
rhesus macaque tetherin. To address this question, stable 293T
cell lines expressing human and rhesus tetherin with HA tags in
their extracellular domains were transfected with bicistronic
constructs that co-express Nef together with green fluorescent
protein (GFP). The extent of tetherin downmodulation was
determined by comparing the mean fluorescence intensity (MFI)
of HA-staining on GFP
+ cells transfected with the empty vector to
the MFI of HA-staining on GFP
+ cells expressing Nef. Consistent
with the species-specific activity of Nef in mediating virus release,
SIV Nef downregulated rhesus tetherin, but did not downregulate
human tetherin (Fig. 5). Moreover, mutations in the myristoylation
site and putative cholesterol recognition motif that impaired the
ability of Nef to facilitate virus release also disrupted its ability to
downregulate rhesus tetherin (Fig. 5). Thus, similar to Vpu [2],
SIV Nef appears to specifically downmodulate cell-surface
expression of rhesus tetherin.
Interferon induces tetherin and inhibits the release of
nef-deleted SIV from an infected rhesus macaque cell line
To determine if deletion of the nef gene also impaired virus
release from an SIV-infected rhesus macaque cell line expressing
physiological levels of tetherin, sMAGI cells, cultured in the
presence and absence of IFNa, were infected with VSV G-
pseudotyped SIV Denv versus SIV DenvDnef. While this cell line did
not express dectable levels of tetherin in the absence of interferon,
treatment with IFNa resulted in the upregulation of tetherin on
the cell surface (Fig. 6A). Although IFNa significantly impaired
virus release for both SIV Denv and SIV DenvDnef, we observed a
much greater reduction in particle release for SIV DenvDnef.
Compared to SIV Denv, p27 release for SIV DenvDnef was reduced
an additional 13.8-fold in IFNa-treated cells (Fig. 6B). Hence,
deletion of the SIV nef gene significantly impaired virus release
from infected cells in the presence of interferon.
The specificity of SIV Nef for rhesus tetherin maps to a
four amino acid sequence in the N-terminus of the
molecule that is not present in human tetherin
Since Nef is a membrane-associated cytosolic protein, we
reasoned that it could potentially associate with the cytoplasmic
domain of tetherin. We therefore exchanged the cytoplasmic
domains of human and rhesus tetherin and tested these
recombinants for susceptibility to SIV Nef. SIV Nef restored
Figure 3. Species-specificity of HIV-1 Vpu and SIV Nef in counteracting restriction by human and rhesus tetherin. HIV-1 Vpu and SIV
Nef were tested for the ability to rescue virus release in trans for SIV Dnef and a vpu-deficient strain of HIV-1 in the presence of human and rhesus
tetherin. 293T cells were transfected in duplicate with 100 ng of proviral DNA for SIV Dnef (A–D) or HIV-1 HXB2 (E–H), 50 ng of DNA for hBST2 or
rBST2, and 100 ng of DNA for either HIV-1 Vpu, SIV Nef, SIV Nef G2A, SIV Nef crm
2 or HIV-1 Nef. G2A and crm
2 represent amino acid substitutions in
the myristoylation site and the cholesterol recognition motif (L129R, Y133A and Y134A) of SIV Nef respectively. Vector controls included pcDNA3 for the
tetherin expression constructs and pCGCG for the Nef expression constructs. Forty-eight hours post-transfection, the amount of virus released into
the cell culture supernatant was measured by SIV p27 (A) or HIV-1 p24 (E) antigen-capture ELISA, and by infectivity on GHOST X4/R5 cells (C,G). To
control for variability due to tetherin-independent effects of Nef and Vpu on particle release, the data are also expressed as percent maximal release
in the absence of tetherin (B,D,F,H). The values above each bar represent the fold-increase in virus release compared to the empty vector control. The
expression of wild-type SIV Nef, Nef G2A, Nef crm-, HIV-1 Nef and HIV-1 Vpu were verified by western blot analysis (I).
doi:10.1371/journal.ppat.1000429.g003
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was fused to the transmembrane and extracellular domain of
human tetherin, but not vice versa, indicating that the ability of
SIV Nef to antagonize rhesus tetherin was dependent on
sequences in the cytoplasmic domain (data not shown).
Amino acid substitutions were therefore introduced into the
cytoplasmic domain of rhesus tetherin at positions that differed
from human tetherin to further define the sequences required for
recognition by SIV Nef (Fig. 7A). Western blot analysis confirmed
the expression of each of these mutants, although there appeared
to be some variability in protein detection (Fig. 7B). Repeated
analysis of the same samples indicated that these differences in
band intensity were in part due to inconsistencies in the detergent
solubility of this transmembrane protein, and thus do not reflect
quantitative levels of protein expression. Substitution of amino
acids 3–5 with the corresponding residues of human tetherin
(S3T4S5), or with alanine residues (A3A4A5), diminished, but did
not eliminate, the effect of Nef on particle release (Fig. 7C).
Furthermore, deletion of the first 10 amino acids (D10) did not
affect the ability of Nef to facilitate virus release (Fig. 7C). These
results therefore implicated the remaining 16-residue membrane
proximal region in recognition by the SIV Nef protein.
The most conspicuous difference between rhesus and human
tetherin in this region was a five amino acid sequence that is
missing from the human molecule. Alanine substitutions were
introduced into this region in the context of the D10 truncation
mutant to investigate the possibility that these sequences
accounted for the specificity of Nef (Fig. 7A). Pair wise alanine
substitutions at positions 14–15 (A14A15) and 16–17 (A16A17)
eliminated the ability of Nef to enhance virus release, while
adjacent substitutions at positions 18–19 (A18A19) did not (Fig. 7C).
These substitutions were also introduced into full-length rhesus
tetherin, and similar to the truncation mutants, the A14A15 and
A16A17 substitutions abrogated the ability of Nef to rescue virion
Figure 4. Expression of the SIV envelope glycoprotein does not rescue virus release. The envelope glycoproteins of SIVmac239, HIV-2
ROD10 and HIV-2 ROD14 were tested for the ability to rescue virus release for SIV DenvDnef in cells expressing human and rhesus tetherin. 293T cells
were transfected with proviral DNA for SIV DenvDnef, an expression construct for hBST2 or rBST2, and an expression construct for either SIVmac239
Env, HIV-2 ROD10 Env, HIV-2 ROD14 Env, SIVmac239 Nef or HIV-1 NL4-3 Vpu. The mean and standard deviation (error bars) are shown for total p27
release (A) and for percent maximal release (B). (C) Protein expression was confirmed for SIV Env, HIV-2 Env, SIV Nef, SIV p55 Gag and BST2 by western
blot analysis of cell lysates. SIV Env was detected with a monoclonal antibody to SIV gp120 (KK42) and HIV-2 Env was detected with rabbit antisera to
HIV-2 ST gp120. The SIV Nef protein was detected with the monoclonal antibody 17.2. SIV p55 Gag, BST2 and b-actin were detected with the
monoclonal antibodies 183-H12-5C, HM1.24 and C4 respectively. Following incubation with an appropriate HRP-conjugated secondary antibody, the
blots were developed in chemiluminescent substrate and visualized using a Fujifilm Image Reader LAS 3000.
doi:10.1371/journal.ppat.1000429.g004
Species-Specificity in Overcoming Tetherin
PLoS Pathogens | www.plospathogens.org 7 May 2009 | Volume 5 | Issue 5 | e1000429release, while the A18A19 substitions did not (Fig. 7D). Moreover,
the introduction of the G14DIWK18 motif from rhesus tetherin
into human tethern resulted in a gain-of-function for susceptibility
to Nef (Fig. 7D). Thus, a four amino acid sequence, G14DIW17,
that is present in the cytoplasmic domain of rhesus tetherin, but
not human tetherin, accounts for the species-specific activity of
SIV Nef against rhesus tetherin.
The specificity of HIV-1 Vpu maps to the membrane-
spanning domain of human tetherin
Recombinants between human and rhesus tetherin were also
tested to identify sequence differences that accounted for the
species-specificity of Vpu. Sequences coding for the cytoplasmic
domains were exchanged to generate rN/hBST2 and hN/rBST2
and sequences coding for the transmembrane domains were
exchanged to generate rTM/hBST2 and hTM/rBST2 (Fig. 8A).
The expression of each of these chimeric fusion proteins was
verified by western blot analysis (Fig. 8B). These recombinants
were then tested for the ability to inhibit virus release in the
presence and absence of Vpu.
Vpu restored particle release for the rN/hBST2 chimera, in
which the cytoplasmic domain of human tetherin was exchanged
with the cytoplasmic domain of rhesus tetherin, but not for the
reciprocal hN/rBST2 chimera (Fig. 8C). Thus, the specificity of
Vpu was not affected by exchanging the cytoplasmic domains of
hBST2 and rBST2. However, susceptibility to Vpu was reversed
by exchanging their transmembrane domains. Replacement of the
transmembrane domain of human tetherin with the corresponding
sequences from rhesus tetherin (rTM/hBST2) abrogated the
ability of Vpu to facilitate virus release (Fig. 8C). For the reciprocal
exchange, replacement of the transmembrane domain of rhesus
tetherin with the transmembrane domain of human tetherin
(hTM/rBST2) resulted in a gain-of-function for Vpu-mediated
particle release (Figs 8C). Hence, these experiments mapped the
specificity of Vpu to the transmembrane domain of human
tetherin. Since Vpu is also an integral membrane protein, and
Figure 5. SIV Nef downregulates rhesus tetherin, but not human tetherin. The ability of Nef to downmodulate tetherin from the cell surface
was assessed by transfecting stable 293T cell lines expressing HA-tagged human or rhesus tetherin (hBST2 or rBST2) with bicistronic constructs
expressing Nef and GFP. SIV Nef, SIV Nef G2A and SIV Nef crm
2 were expressed from the same mRNA transcript as GFP using pCGCG constructs in
which expression of the GFP reporter gene was driven from an internal ribosomal entry site downstream of nef. Cells were also transfected with
pCGCG without nef as an empty vector control. Twenty-four hours after transfection, the cells were stained with an anti-HA monoclonal antibody
followed by an APC-conjugated, donkey anti-mouse polyclonal antibody and analyzed by flow cytometry. The values indicated in each plot represent
the mean fluorescence intensity and standard deviation of HA/BST2 staining on GFP
+ cells for duplicate transfections.
doi:10.1371/journal.ppat.1000429.g005
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macaque sMAGI cell line was cultured in the presence or absence of IFNa, and virus release was compared following infection with VSV G-
pseudotyped SIV Denv versus SIV DenvDnef. (A) Treatment with IFNa upregulated the expression of tetherin on the cell surface. Cells were cultured in
medium with or without 1000 U/ml IFNa, and the expression of tetherin was assessed by flow cytometry. (B) Deletion of the SIV nef gene significantly
impaired virus release from infected cells in the presence of IFNa. Seventy-two hours after infection with VSV G-pseudotyped SIV Denv and SIV
DenvDnef (50 ng/ml p27 eq. each), the amount of p27 released into the cell culture supernatant was determined by antigen capture ELISA.
doi:10.1371/journal.ppat.1000429.g006
Figure 7. Identification of the residues in rhesus tetherin required for recognition by SIV Nef. (A) Amino acid substitutions were
introduced into full-length rBST2 and a deletion mutant lacking the first ten amino acids (rBST2 D10) at positions that differ from hBST2. The
G14DIWK18 motif of rBST2 was also introduced into hBST2 (hBST2 G14DIWK18). Dashes represent sequence gaps, and positions that differ from wild-
type rBST2 are indicated in red. (B) Expression of each of the rBST2 mutants tested in (C) was confirmed by western blot analysis of transfected 293T
cell lysates. (C,D) SIV Nef was tested for the ability to rescue virus release for SIV Dnef in cells expressing each of the rBST2 and hBST2 mutants shown
in (A). Transfection and assay conditions were the same as previously described.
doi:10.1371/journal.ppat.1000429.g007
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the ability to enhance virion release [61,62,63], these results
suggest that the mechanism by which Vpu antagonizes tetherin
may involve interactions between the transmembrane domains of
these proteins.
Nef alleles of SIVsmm/mac, HIV-2 and HIV-1 counteract
rhesus macaque and sooty mangabey tetherin, but are
generally ineffective against human tetherin
Nef alleles of SIVsmm/mac, HIV-2 and HIV-1 were tested for the
ability to rescue particle release in cells expressing rhesus macaque,
sooty mangabey and human tetherin. Similar to SIVmac239 Nef,
Nef alleles of two primary SIVsmm isolates, SIVsmmFYr1 and
SIVsmmFWr1, enhanced virus release in the presence of rhesus
macaque tetherin (Fig. 9B & C). These alleles also enhanced virus
release from cells expressing sooty mangabey tetherin to a similar
extent as SIVmac239 Nef (Fig. 9B & C). These observations are
supported by western blots showing consistent levels of Nef and p55
Gag expression in each set of transfections (Fig. 9D). The bands for
human, rhesus macaque and sooty mangabey tetherin were more
variable,butneverthelessprovidedqualitative verificationofprotein
expression (Fig. 9D). These results therefore suggest that the ability
of Nef to oppose tetherin was likely retained upon cross-species
transmission of SIVsmm from sooty mangabeys to rhesus macaques.
Although somewhat less efficiently, Nef alleles of HIV-1 and
HIV-2 also rescued virus release in the presence of rhesus
macaque and sooty mangabey tetherin (Fig. 9B & C). Thus, the
ability of Nef to counteract tetherin from these Old World
monkeys appears to be broadly conserved among the primate
lentiviruses. However, with the exception of HIV-1 NA7 Nef,
none of the Nef alleles tested appreciably restored virus release in
cells expressing human tetherin. Interestingly, HIV-1 NA7 Nef
was particularly effective at facilitating virus release in the presence
of sooty mangabey tetherin (Fig. 9B & C). Since the cytoplasmic
domains of rhesus macaque and sooty mangabey tetherin only
differ by two amino acids C9R10, and these residues are present in
both the human and sooty mangabey molecules (Fig. 9A), it is
conceivable that adaptation of HIV-1 NA7 for partial activity
against human tetherin may have resulted in greater activity
against the sooty mangabey molecule.
Discussion
Tetherin (BST2, CD317 or HM1.24) was recently identified as
an interferon-inducible restriction factor that interferes with the
detachment of HIV-1 from infected cells in the absence of the Vpu
accessory protein [1,2]. While this factor appears to have broad
activity against diverse retroviruses [1,2,27], as well as other
families of enveloped viruses [25,26,27], only two phylogenetic
Figure 8. The sequences required for Vpu recognition of human tetherin map to the transmembrane domain. (A) Sequences
corresponding to the cytoplasmic domain (N) and transmembrane domain (TM) of human and rhesus tetherin (hBST2 and rBST2) were exchanged to
generate the chimeric fusion proteins rTM/hBST2, hTM/rBST2, rN/hBST2 and hN/rBST2. Amino acid sequences corresponding to the predicted
transmembrane domains are boxed, dashes represent sequence gaps, and positions in hBST2 that differ from rBST2 are indicated in red. (B) The
expression of each of these recombinant proteins was verified by western blot analysis. (C) Vpu was tested for the ability to rescue p24 release for
HIV-1 HXB2 in 293T cells expressing hBST2, rBST2, rTM/hBST2, hTM/rBST2, rN/hBST2 and hN/rBST2. Transfection and assay conditions were the same
as described previously.
doi:10.1371/journal.ppat.1000429.g008
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PLoS Pathogens | www.plospathogens.org 10 May 2009 | Volume 5 | Issue 5 | e1000429Figure 9. Nef alleles of SIVsmm/mac, HIV-2 and HIV-1 counteract rhesus macaque and sooty mangabey tetherin, but not human
tetherin. Nef alleles of SIVsmm/mac, HIV-2 and HIV-1 were tested for the ability to rescue particle release for SIV Dnef in the presence of human
tetherin (hBST2), rhesus macaque tetherin (rBST2) and sooty mangabey tetherin (sBST2). (A) The amino acid sequences corresponding to the
cytoplasmic domains of hBST2, rBST2 and sBST2 are shown. Dashes represent sequence gaps and residues that differ from rBST2 are indicated in red.
The mean and standard deviation (error bars) for total p27 release (B) and for percent maximal release (C) are shown for the indicated Nef alleles of
SIVsmm/mac, HIV-2 and HIV-1 in the presence of hBST2, rBST2 and sBST2. (D) Protein expression was confirmed for SIV p55 Gag, BST2, HIV-1 Vpu and for
each of the Nef alleles by western blot analysis of 293T cell lysates. The Nef proteins of SIVmac239 and SIVsmm (FYr1 and FWr1) were detected using
plasma pooled from SIV-infected rhesus macaques and SIV-infected sooty mangabeys respectively. The Nef proteins of HIV-2 ROD10, ROD14, CBL-23
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are known to express Vpu [21,22,23,24]. Lentiviruses of the HIV-
2/SIVsmm/mac lineage do not have a vpu gene. Thus, understand-
ing how these viruses overcome restriction by tetherin is of
significant evolutionary interest and may have important implica-
tions to our understanding of the host-range specificity of the
primate lentiviruses. We therefore set out to determine how SIV
overcomes this restriction in the rhesus macaque, an important
animal model for lentiviral pathogenesis and for AIDS vaccine
development.
In the presence of rhesus tetherin, deletion of the SIV nef gene
greatly impaired virus release compared to wild-type SIV.
Expression of the SIV Nef protein in trans rescued virus release
from cells expressing rhesus tetherin, thereby suggesting a role for
Nef in overcoming this restriction in SIV-infected macaques.
However, SIV Nef did not enhance virus release in the presence of
human tetherin. In the case of HIV-1 Vpu, the situation was
reversed. HIV-1 Vpu facilitated virus release in the presence of
humantetherin,butnot inthepresenceofrhesustetherin.Thus,the
activities of both HIV-1 Vpu and SIV Nef in counteracting
restriction by tetherin arespecies-specific.These results suggest that,
similar to TRIM5a and APOBEC3G [40,41,42,43,48,49,50],
species-specific differences in tetherin contribute to the host-range
specificity of HIV-1 and SIV.
Deletion of the SIV env gene also impaired virus release from
cells transfected with proviral DNA. Compared to the deletion of
nef, this effect was lower and did not appear to be specific for either
human or rhesus tetherin. Since the envelope glycoproteins of
certain HIV-2 isolates, such as ROD10 and ST, have Vpu-like
activity that can enhance the release of diverse retroviruses from
otherwise restrictive cell types [28,29,30,31], and the Ebola
glycoprotein was recently shown to counteract tetherin [26], this
raised the possibility that the envelope glycoprotein of SIV might
also antagonize restriction by tetherin. However, under conditions
of envelope overexpression, in which the HIV-2 ROD Env could
partially rescue particle release, we did not observe a significant
effect of SIV Env on virus release. While these results do not
preclude a minor contribution of the SIV envelope glycoprotein,
they suggest that Nef is the predominant viral gene product by
which SIV counteracts restriction by tetherin.
The specificity of SIV Nef for rhesus tetherin mapped to a four
amino acid sequence, G14DIW17, in the cytoplasmic domain of the
molecule. These residues closely coincide with a five amino acid
sequence, G14DIWK18, that is missing from human tetherin [64].
Comparison of the predicted amino acid sequences of human
versus chimpanzee tetherin revealed that a similar five amino acid
sequence (D14DIWK18) was retained in the cytoplasmic domain of
the chimpanzee orthologue [65]. This suggests that a recent 15-
nucleotide deletion, that occurred since the divergence of humans
and chimpanzees from a common ancestor approximately 5
million years ago [65], accounts for the inability of Nef to
counteract restriction by human tetherin. It is therefore tempting
to speculate that our ancestors may have encountered a viral
pathogen, perhaps a lentivirus related to SIV, that selected for the
loss of these sequences at some point during the course of human
evolutionary history.
The residues required for SIV Nef recognition of rhesus tetherin
are also present in the cytoplasmic domain of sooty mangabey
tetherin, and Nef alleles of primary SIVsmm isolates were able to
overcome restriction by tetherin orthologues from both of these
Old World primate species. Thus, the ability of SIV Nef to oppose
tetherin appears to have been conserved upon cross-species
transmission of SIVsmm from sooty mangabeys to rhesus macaques
[32,34,36]. Although somewhat less efficiently, Nef alleles of HIV-
1 and HIV-2, were also able to rescue virus release in cells
expressing sooty mangabey and rhesus macaque tetherin. These
observations suggest that conserved sequences in Nef, maintained
perhaps as a consequence of their role in other functional
activities, may contribute to a basal level of activity against
macaque and mangabey tetherin. However, consistent with the
absence of sequences in the cytoplasmic domain essential for
recognition by Nef, none of the Nef alleles tested, with the possible
exception of HIV-1 NA7 Nef, rescued virus release in the presence
of human tetherin. Hence, this may explain why this activity
appears to have been assumed by the envelope glycoproteins of
certain HIV-2 isolates [28,29,30,31].
HIV-1, and other enveloped viruses, assemble and bud from
cholesterol-rich lipid rafts at the plasma membrane
[15,16,17,18,19]. Nef localizes to lipid rafts and increases virus
budding and infectivity [66,67]. Since tetherin also associates with
lipid rafts by virtue of its GPI anchor [13], the ability of Nef to
counteract tetherin may be dependent on its association with
cellular membranes and targeting to lipid rafts. Consistent with
this possibility, amino acid substitutions in the myristoylation site
and a putative cholesterol recognition motif of SIV Nef impaired
its ability to counteract rhesus tetherin.
Although the mechanism by which Nef counteracts tetherin
remains to be fully defined, we found that SIV Nef could
downregulate rhesus tetherin from the cell surface. As with the
ability to rescue particle release, this activity was species-specific,
since SIV Nef was unable to downregulate human tetherin.
Furthermore, mutations in the myristoylation site and cholesterol
recognition motif that impaired the ability of Nef to facilitate virus
release also disrupted its ability to downmodulate rhesus tetherin.
These results suggest that, similar to the previously documented
ability of Vpu to dowmodulate human tetherin [2], the
downregulation of rhesus tetherin by Nef may contribute to the
ability of SIV to overcome this restriction in Old World primates.
Treatment with IFNa upregulated tetherin and impaired the
release of nef-deleted SIV from an infected rhesus macaque cell
line. These results confirmed that the expression of tetherin on
rhesus macaque cells is interferon-inducible, and similar to HIV-1
Dvpu infection of human cells [11], SIV Dnef is particularly
sensitive to IFNa. Regulation of tetherin by interferon may
explain, at least in part, why deletion of the nef gene does not result
in a more complete block to SIV replication in primary PBMC.
While Nef clearly confers an advantage to SIV replication in
primary macaque lymphocytes [55], depending on the culture
conditions, SIV Dnef can replicate nearly as well as wild-type virus.
In the absence of interferon, low basal levels of tetherin on primary
CD4
+ lymphocytes may not impose a stringent barrier to virus
replication.
A role for Nef in overcoming restriction by tetherin may,
nevertheless, help to explain the attenuated phenotype of nef-
deleted strains of SIV in rhesus macaques [68,69]. Peak viral loads
in animals infected with SIV Dnef are typically 1.5 logs lower than
and 60415K were detected using plasma pooled from HIV-2-infected individuals. The Nef proteins of HIV-1 NL4-3 and NA7 were detected using
polyclonal rabbit antisera. SIV p55 Gag, BST2 and b-actin were detected with the monoclonal antibodies 183-H12-5C, HM1.24 and C4. Following
incubation with an appropriate HRP-conjugated secondary antibody, the blots were developed in chemiluminescent substrate and visualized using a
Fujifilm Image Reader LAS 3000.
doi:10.1371/journal.ppat.1000429.g009
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Greater susceptibility to inhibition by tetherin may contribute to
this attenuated phenotype, particularly during the acute phase of
infection prior to the onset of adaptive immunity. However, the
loss of a number of other functional activities of Nef may also play
a role, including CD4 downregulation [70], selective MHC class I
downregulation [71], cellular activation [72], and infectivity
enhancement [59]. Additional studies to differentiate the role of
Nef in opposing tetherin from its other functional activities will be
necessary to ascertain the relative importance of the loss of this
activity to the attenuation of SIV Dnef.
Infection of macaques with simian-human immunodeficiency
virus (SHIV) strains in which the nef sequences of SIVmac239 were
replaced by nef alleles of HIV-1 demonstrated that HIV-1 Nef can,
at least in part, substitute for SIV Nef to facilitate virus replication
in vivo. Of 19 animals infected with these SHIVnef strains, 11
maintained moderate to high viral loads and 8 progressed to AIDS
within 1–2 years of infection [73]. HIV-1 nef sequences were
retained in all animals and sequence changes predicted to optimize
translation were observed suggesting that the expression of HIV-1
Nef conferred an advantage to virus replication [73]. Nevertheless,
while the viral loads in these animals were generally higher than in
animals infected with SIV Dnef, they were not as high, or as
consistent, as viral loads typically observed in animals infected with
wild-type SIVmac239 [73]. This intermediate phenotype is
consistent with our present observations indicating that HIV-1
Nef is poorly adapted for counteracting viral inhibition by rhesus
tetherin. Although Nef alleles of HIV-1 were less effective than Nef
alleles of SIV, HIV-1 Nef appears to have a basal level of activity
against rhesus tetherin. Partial activity of HIV-1 Nef against rhesus
tetherin, together with other conserved activities of the protein,
such as cellular activation and infectivity enhancement [59,72],
may account for the replicative advantage of SHIVnef relative to
SIV Dnef. However, incomplete adaptation to rhesus tetherin may
also have contributed to the somewhat more attenuated phenotype
of these viruses compared to wild-type SIV.
Similar to previous reports [1,2,52], we observed a greater effect
of Vpu when HIV-1 release was measured by an infectivity assay
than by an assay for viral antigen. In the presence of human
tetherin, expression of the Vpu protein in trans resulted in a 27.1-
fold increase in the amount of infectious virus versus a 3.7-fold
increase in the amount of p24 for a vpu-deficient strain of HIV-1.
Unlike the infectivity enhancement afforded by Nef, this effect was
dependent on human tetherin and was only observed for HIV-1.
Hence, this activity appears to be directly related to the role of
Vpu in overcoming restriction by tetherin. This suggests that, in
addition to facilitating the detachment of virus particles from
infected cells, Vpu may also play a role in infectivity enhancement.
One possibility is it that Vpu-mediated downregulation and
degradation of tetherin may prevent the incorporation of tetherin
into virions and reduce the formation of viral aggregates, as
suggested by some electron micrographs [1,11]. This would
effectively increase the titer of infectious virus, since more particles
would be available to infect a greater number of cells.
Alternatively, the observed increase in infectivity may be related
to the recently reported effect of Vpu on preventing the
accumulation of Env in late endosomes [74]. By inhibiting Env
transport to endosomes, Vpu may facilitate the incorporation of
Env into virions assembling at the plasma membrane, thereby
increasing particle infectivity.
Vpu has a transmembrane anchor at its N-terminus, and
mutations within this region disrupt its ability to facilitate virion
release [61,62,63]. Van Damme et al. further demonstrated that
the correct amino acid sequence of the Vpu transmembrane
domain is required for downmodulation of tetherin from the cell
surface [2]. By exchanging the membrane-spanning domains of
human and rhesus tetherin, we mapped the sequences responsible
for Vpu recognition to the transmembrane domain of human
tetherin. This finding was independently verified by McNatt et al.
in a recent study showing that a combination of amino acid
differences within the transmembrane domain, rather a single
amino acid subsitution, accounted for differences in the suscep-
tibility of human and rhesus tetherin to Vpu [51]. These results
suggest that the mechanism by which Vpu antagonizes tetherin
likely requires specific interactions, either direct or via a bridging
factor, between the transmembrane domains of Vpu and tetherin.
The inability of Vpu to counteract restriction by rhesus tetherin
represents a potential additional barrier to HIV-1 replication in
macaques. Efforts to overcome the known species-specific blocks to
HIV-1 infection of macaques imposed by TRIM5a and
APOBEC3G have led to the construction of recombinant HIV-1
strains containing SIV capsid and Vif sequences [75,76]. These
chimeric viruses replicate efficiently in PBMCs from rhesus and
pig-tailed macaques [75,76], but are unable to sustain persistent,
high-level virus replication in animals [77,78]. Unlike APO-
BEC3G and TRIM5a, tetherin does not represent an absolute
block to infection, but may serve to attenuate virus replication in
the absence of effective viral countermeasures. Thus, the
susceptibility of these HIV-1 recombinants to restriction by
tetherin, perhaps under conditions of interferon-induction in vivo,
may contribute to the inability of these viruses to replicate
efficiently in animals. The introduction of additional sequence
changes to overcome restriction by tetherin in macaques therefore
represents a promising approach for further adapting HIV-1 for
replication in non-human primates.
Materials and Methods
Plasmid DNA constructs
(i) BST 2 expression constructs. Human BST2 (hBST2) was
amplified by PCR from a cDNA clone obtained from the Harvard
Plasmid Database. Rhesus macaque and sooty mangabey BST2
(rBST2) were amplified by RT-PCR from mRNA isolated from
lymphocytes. BST2 sequences were cloned into the Kpn I and Xho I
sites of pcDNA3 (Invitrogen, Carlsbad, CA). Amino acid
substitutions were introduced into rhesus BST2 by QuickChange
site-directed mutagenesis (Stratagene, La Jolla, CA) of pcDNA3-
rBST2. Recombinants of human and rhesus tetherin were
generated by PCR overlap extension [79] using both human
and rhesus tetherin as template and cloned into pcDNA3. All
plasmid DNA expression constructs were sequence confirmed.
(ii) HIV-1 and SIV clones. Full-length clones for SIVmac239,
SIVmac239 Denv, SIVmac239 Dnef and SIVmac239 DenvDnef were
constructed from previously described deletion mutants based on
p239SpSp59, pSP72-239-39, pSP72-239-39DEnv and pSP72-239-
39Dnef [68,80,81,82]. HIV-1 NL4-3 (pNL4-3) was obtained
through the AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH from Dr. Malcolm Martin [83].
The vpu-deleted clone of HIV-1 NL4-3 (HIV-1 Dvpu) was made by
deleting nucleotide 16 of vpu, which resulted in a frame shift
followed by multiple in-frame stop-codons. This clone was
provided by Dr. Swee Kee Wong (New England Primate
Research Center, Harvard Medical School). The HIV-1 HXB2
clone pHXB2 does not express Vpu as a result of a defective ACG
start-codon. This clone also contains an additional frame shift
mutation in vpr and premature stop-codons in tat and nef [84,85].
(iii) Nef, Vpu and Env expression constructs. The SIV
Nef expression construct pCGCG-239-Nef was provided by Dr.
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Harbor, NY) [86]. Constructs expressing SIV Nef mutants with
amino acid substitutions in the N-terminal myristoylation site
(G2A) and the cholesterol recognition motif (crm
2;L 129R, Y133A
and Y134A) were created by site directed mutagenesis of pCGCG-
239-Nef. Additional constructs expressing Nef alleles of
SIVsmmFYr1, SIVsmmFWr1, HIV-2 ROD10, HIV-2 ROD14,
HIV-2 CBL-23, HIV-2 60415K, HIV-1 NL4-3 and HIV-1 NA7
HIV-1 were generated by introducing PCR-amplified nef
sequences into the Xba I and Mlu I sites of pCGCG. The Nef
alleles of SIVsmmFYr1, SIVsmmFWr1, HIV-2 CBL-23, HIV-2
60415K, HIV-1 NL4-3 and HIV-1 NA7 were amplified from
HIV-1 NL4-3 based expression constructs provided by Dr. Frank
Kirchhoff (Institute of Virology, Universita ¨tsklinikum, Ulm,
Germany) [87], and the Nef alleles of HIV-2 ROD10 and HIV-
2 ROD14 were amplified from pROD10 and pROD14 provided
by Dr. Klaus Strebel (NIAID, Bethesda, MD) [28,30]. The codon-
optimized Vpu expression construct pcDNA-Vphu was obtained
through the AIDS Research and Reference Reagent Program
from Dr. Stephan Bour and Dr. Klaus Strebel [88]. The codon-
optimized SIV Env expression construct 64S was obtained from
Dr. George Pavlakis (NCI-Frederick, Frederick, MD) [89]. The
expression constructs pSA91-HIV-2 ROD10 and pSA91-HIV-2
ROD14 for the HIV-2 ROD10 and ROD14 envelope
glycoproteins were provided by Dr. Paula Cannon (Childrens
Hospital, Los Angeles, CA) [31].
Virus release assays
To assay for virus restriction, 293T cells were co-transfected
with proviral DNA clones based on HIV-1 NL4-3 (20 ng) and
SIVmac239 (100 ng) together with pcDNA3-based expression
constructs for either human or rhesus tetherin (0–200 ng of
pcDNA3-hBST2 or pcDNA3-rBST2). Differences in the amount
of plasmid DNA in each transfection were offset by the addition of
the empty pcDNA3 vector (0–200 ng). To assay for the ability of
Vpu and Nef to rescue virus release in the presence of tetherin,
293T cells were co-transfected with; (1) proviral DNA for either
SIVmac239 Dnef or HIV-1 HXB2 (100 ng), (2) pcDNA3-based
expression constructs for human tetherin (pcDNA3-hBST2),
rhesus macaque tetherin (pcDNA3-rBST2), sooty mangabey
tetherin (pcDNA3-sBST2) or an empty vector control (pcDNA3)
(50 ng), and (3) expression constructs for Vpu (pcDNA-Vphu), Nef
(pCGCG-239-Nef and derivatives) or vector alone (pCGCG)
(100 ng). Transfections were performed in duplicate in 24-well
plates seeded the day before at 5610
4 cells per well using GenJet
Lipid Transfection Reagents (SignaGen Laboratories, Gaithers-
burg, MD). Forty-eight hours after transfection, the amount of
virus released into the cell culture supernatant was measured by
SIV p27 and HIV-1 p24 antigen-capture ELISA (Advanced
Bioscience Laboratories, Inc., Kensington, MD). The percentage
of maximal particle release was calculated by dividing the mean
p24/p27 release in the presence of tetherin by the mean p24/p27
release in the absence of tetherin and multiplying by 100.
Infectivity assays
The amount of infectious virus present in the cell culture
supernatant was measured by infection of GHOST X4/R5 cells
[50]. These cells harbor a Tat-inducible GFP reporter gene and
are susceptible to both HIV-1 and SIV infection by virtue of
expressing CD4, CXCR4 and CCR5. The GHOST (3) X4/R5
cells were obtained through the AIDS Research and Reference
Reagent Program from Dr. Vineet N. KewalRamani and Dr. Dan
R. Littman [53]. These cells were seeded at 2.5610
4 cells per well
in 24-well plates, and infected the following day by replacing the
medium with 100 ml of culture supernatant from 293T cells
transfected with HIV-1 or SIV proviral DNA. After 2 hours, the
culture volume was brought to 2 ml with fresh medium. Forty-
eight hours later, the cells were trypsinized, fixed in 2%
paraformaldehyde/PBS and analyzed by flow cytometry. The
data were collected using a FACSCalibur flow cytometer (Becton
Dickenson, San Jose, CA) and analyzed using FlowJo 8.7 software
(TreeStar, San Carlos, CA).
Western blots
Virions were recovered from cell culture supernatants at
13,000 rpm for 2 hours at 4uC and virus pellets were resuspended
in 26 sodium dodecyl sulfate (SDS) sample buffer. Cell lysates
were prepared by harvesting cells in 26 SDS sample buffer.
Samples were boiled for 5 minutes, separated by electrophoresis
on 10% SDS-polyacrylamide gels and transferred to polyvinyli-
dene fluoride (PVDF) membranes using a Trans-Blot SD semidry
transfer cell (Bio-Rad, Hercules, CA). The membranes were then
blocked in 5% non-fat milk-PBS containing 0.05% Tween-20 for
1 hour and probed overnight with the following primary
antibodies at 4uC. SIV p27 and p55 were detected using a
cross-reactive monoclonal antibody to HIV-1 p24 (183-H12-5C)
at a dilution of 1:1000. Human and rhesus tetherin were detected
using the monoclonal antibody HM1.24, generously provided by
Chugai Pharmaceutical Co. (Kanagawa, Japan), at a dilution of
1:2000. SIV Nef was detected using the 17.2 monoclonal antibody
at a dilution of 1:1000. SIV Env was detected using the KK42
monoclonal antibody at a 1:1000 dilution. HIV-2 Env was
detected using rabbit antisera to HIV-2 ST gp120 at a 1:1000
dilution. HIV-1 Nef and Vpu were detected using polyclonal
rabbit sera at dilutions of 1:500. b-actin was detected using the
monoclonal antibody C4 (Chemicon, Billerica, MA) at a dilution
of 1:1000. The antibodies to SIV Nef, SIV Env, HIV-2 Env, HIV-
1 p24, HIV-1 Nef and HIV-1 Vpu were all obtained through the
AIDS Research and Reference Reagent Program, NIAID, NIH.
Pooled plasma from SIV-infected sooty mangabeys, provided by
Dr. Amitinder Kaur (New England Primate Research Center,
Harvard Medical School), was used at dilution of 1:200 for the
detection of SIVsmm Nef. Pooled plasma from HIV-2-infected
individuals, provided by Dr. Walid Heneine (Centers for Disease
Control and Prevention, Atlanta, GA), was used at a dilution of
1:200 for the detection of HIV-2 Nef. After washing in PBS 0.05%
Tween-20, blots were probed with HRP-conjugated secondary
antibodies, either goat anti-mouse IgG (Pierce, Rockford, IL) or
goat anti-rabbit IgG (Sigma), at dilutions of 1:2000 for 1 hour.
Blots were then washed, developed with SuperSignal West Femto
Maximum Sensitivity substrate (Pierce), and bands were visualized
using a Fujifilm Image Reader LAS 3000 phosphoimager (Fujifilm
Photo Film Co., Japan). The pixel intensities for the p27 and p55
bands in virions and cell lysates respectively were determined using
the Image J Software (Rasband, W.S., Image, U.S. NIH,
Bethesda, MD, http://rsb.info.nih.gov/ij, 1997–2008) as previ-
ously described [27].
Downregulation assay
Stable 293T cell lines expressing HA-tagged human and rhesus
tetherin were established by retroviral transduction. An oligonu-
cleotide encoding the HA tag was inserted in-frame into the Mlu I
sites of rBST2 and hBST2 resulting in the introduction of the 9
amino acid HA epitope after residue 131 of hBST2 and after
residue 134 rBST2. These HA-tagged BST2 sequences were then
subcloned into the Age I and Pac I sites of the retroviral vector
pQCXIP (Clonetech Laboratories, Mountainview, CA). VSV G-
pseudotyped MLV particles packaging these vectors were
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used to infect 293T cells. Stable cell lines were selected in medium
containing puromycin (4 mg/ml) and enriched for BST2 expres-
sion by FACS after staining with the PE-conjugated, anti-HA
monoclonal antibody HA.11 (Covance, Emeryville, CA).
Cells expressing HA-tagged human and rhesus tetherin were
plated at a density of 5610
4 cells per well in 24 well plates and
transfected the following day with pCGCG-based constructs
(200 ng) that co-express Nef and GFP. After 24 hours, the cells
were trypsinized and stained with the anti-HA monoclonal
antibody HA.11 for 30 minutes at 4uC. The cells were then
washed and stained with an APC-conjugated, donkey anti-mouse
IgG polyclonal antibody (eBioscience, San Diego, CA) for
30 minutes at 4uC. The cells were washed, fixed in 2%
paraformaldehyde PBS and analyzed using a FACSCalibur flow
cytometer (Becton Dickenson, San Jose, CA). The data were
analyzed using FlowJo 8.7 software (TreesStar, San Carlos, CA).
Infection of interferon-treated sMAGI cells with VSV G-
pseudotyped SIV Denv and SIV DenvDnef
The rhesus macaque sMAGI cell line was obtained through the
AIDS Research and Reference Reagent Program from Dr. Julie
Overbaugh [90]. Cells were seeded to 24 well plates at a density of
1610
5 cells per well in medium lacking or containing 1000 U/ml
IFNa (Sigma, St. Louis, MO). The following day, duplicate wells
were infected with 50 ng p27 eq. of VSV G-pseudotyped SIV Denv
and SIV DenvDnef. The medium was replaced after 24 hours
continuing with or without IFNa. On day 3 post-infection, the
accumulation of p27 in the cell culture supernatant was measured
by antigen capture ELISA. The upregulation of tetherin in
response to IFNa was assessed by staining sMAGI cells with a
FITC-conjugated monoclonal antibody to tetherin (Chugai
Pharmaceutical Co.).
Genbank accession numbers
Human tetherin [D28137]; rhesus macaque tetherin
[FJ868941]; sooty mangabey tetherin [FJ864713]; SIVmac239
Nef [M33262]; SIVsmmFYr1 Nef [DQ092760]; SIVsmmFWr1 Nef
[DQ092758]; HIV-2 CBL-23 Nef [DQ222472]; HIV-2 60415K
Nef [DQ092764]; HIV-1 NL4-3 Nef [M19921]; HIV-1 NA7 Nef
[DQ242535].
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